

AMGEN FRANCE GOLDEN TICKET

GENERAL CONDITIONS OF THE CALL FOR PROJECTS 2024

Preamble

As part of its partnership with Biolabs Hôtel-Dieu, Amgen France proposes to launch a call for projects and to award two "golden tickets" among the candidates who have met the selection criteria and who will be designated as Winners according to the terms set out below.

By participating in this call for projects and submitting an application, the applicant agrees to abide by these terms and conditions and the decisions of Amgen France, which shall be final and binding in all respects, including Amgen's right to verify eligibility, to interpret, to otherwise modify these terms and conditions and to resolve any claim or dispute relating to the competition at any time, in any manner, at its sole discretion.

Call for projects

1. Object

Amgen France launches the call for projects for the "Golden Ticket" program and invites interested startups in life sciences, biotechnology and digital health to submit their applications.

These terms and conditions apply to the call for projects.

The call for projects is open to any entity with legal personality, recently created and/or under development, whose aim is to develop innovative solutions in the field of digital health or life sciences.

The projects proposed as part of the application process must be innovative and either fall within the following therapeutic areas: cardiovascular, metabolic, rare diseases, inflammation, oncology, and hematology, or emerging technology platforms in the fields of R&D, precision medicine, and data science (AI, organoids, etc.), or provide added value in health activities - including research - and life sciences.

Candidates can submit their applications from September 5, 11:00 a.m. to October 7, 6:00 p.m. at the latest via the following link: <https://lf5da1tbxim.typeform.com/to/fyvHZQM1>

2. Eligibility criteria

Each applicant must be eligible to participate in the call for projects and comply with the conditions set out below. Failure to do so may result in rejection by Amgen.

To be eligible for the call for projects, applicants must have a legal entity, and undertake to provide proof of this as part of their application (e.g. K-Bis less than 3 months old). The legal structure of the applicant(s) must be based in France (DROM-COM included).

AMGEN FRANCE

GOLDEN TICKET 2024 - FRA-NP-0824-80010 – SEPTEMBER 2024

Natural persons are not eligible to participate in the Call for Projects, including in particular :

- All employees, trainees and work-study students - of Amgen France or any other company in the Amgen group - are eligible to apply.
- Any healthcare professional within the meaning of the French Public Health Code (including interns).

Also not eligible are associations of healthcare professionals, patient associations and any structure/center involved in the organization of healthcare.

Candidates must not have won a previous Amgen Golden Ticket within the previous three years.

Applicants must agree to abide unreservedly by the rules of the call for projects, as well as current legislation and regulations. They must also comply with the ethical and deontological rules set out in section 7 "Anti-corruption declarations and guarantees" below.

3. How to submit

The application file consists of :

- The completed English application form available [here](#)
- These approved and signed rules and conditions of the call for projects
- A non-confidential presentation of up to 15 slides in English

Each candidate may submit only one application for a single project. Applications will not be acknowledged or returned. Amgen is not responsible for applications that, for any reason, are lost, late or misdirected, for malfunctions of electronic equipment, computer hardware or software, for problems with downloading or data entry or other technical problems, or for human error in connection with the application submission process.

The application process begins at 11:00 a.m. Central European Time on September 5, 2024 and ends at 6:00 p.m. Central European Time on October 7, 2024 (the "Closing Date"). Applications received after the Closing Date and Time will not be considered. The application period may be extended at the discretion of Amgen France.

By submitting an application, the participant warrants and represents that:

- The entry is the original work of the participant;
- The participant and, where applicable, the participating team, have consented to the submission of the entry to the competition;

iii. The entry does not contain any copyrighted material not belonging to the entrant or, where applicable, the participating team and, to the best of the entrant's knowledge, does not infringe the rights of any third party, including, but not limited to, rights of publicity or privacy, moral rights or any other proprietary rights;

As part of its application, the participant may provide references on partnerships set up with third-party companies.

The presentation included in the application file must include the following elements:

- Maximum 15 slides,
- Company mission and therapeutic area, if applicable
- A clear description of the technology
- At least 1 slide detailing the skills, expertise and capabilities of each member of the project team.
- At least 3 slides presenting convincing data (with appropriate controls, labels and accurate interpretation) and steps taken to secure intellectual property on the project applied for.
- Key milestones and hurdles ahead (including financing)
- The project's target market, development strategy and financing methods, including future financing.
- At least one slide detailing the expected benefits of obtaining an Amgen Golden Ticket and the motivation to join the Biolabs Hôtel-Dieu site.

Entries will be treated as non-confidential. By submitting an Entry, the Entrant acknowledges and agrees that the Entry will not be treated as confidential. Before submitting an Entry, the Entrant is advised to consult a lawyer or patent attorney as to the advisability of applying for patents or other protection for the Entry.

4. Evaluation process and criteria

Each application meeting the eligibility criteria will be submitted to a Jury made up of experts previously identified and selected by Amgen.

The Jury for the Call for Projects is made up of representatives of Amgen - from the French subsidiary or other international entities - heading departments or divisions in the medical or innovation fields. The Jury is empowered to select a maximum of five candidates as finalists.

From these Finalists, two winners will be selected no later than December 15, 2024. Each Finalist will be contacted at the e-mail address provided in the application. If contacted, the Finalist must respond to this request to remain eligible to win the prize. If an acknowledgement of selection is not received by email at golden.ticket.paris@amgen.com within three (3) business days of notification, the Finalist

AMGEN FRANCE

GOLDEN TICKET 2024 - FRA-NP-0824-80010 – SEPTEMBER 2024

will be deemed to have withdrawn from the Call for Entries and another Finalist will be selected, if applicable. Amgen assumes no responsibility for lost, delayed or misdirected communications or for any computer, online or technical malfunctions that may occur. Only Participants who have complied with all applicable deadlines and requirements may be selected as Winners.

Finalists will submit and give a non-confidential presentation followed by a Q&A session at an in-person Amgen Final Selection Event to be held in December 2024. Any Finalist who does not attend the Event, for whatever reason, will no longer be eligible to receive the Golden Ticket. At the end of the final selection, the jury will decide on the awarding of the 2 Golden Tickets. The Winners will be announced on the day of the Event. If the Winner decides to decline the prize for any reason, Amgen will have no further obligation to that Finalist and the Prize will be forfeited and may be awarded to a second Finalist, at Amgen's discretion.

The Jury's decision is final and cannot be contested.

The Jury will evaluate all applications based on the following criteria:

- Quality of the science and scientific reasoning: description of the scientific reasoning and unique technical characteristics of the proposed solution, summary of proof-of-concept data;
- Strategic alignment with Amgen's current therapeutic areas;
- Need and development potential in the applicable field: (i) description of the unmet problem/need addressed by the project and the suitability of the proposed solution to the unmet need, and (ii) description of the proposed development pathways in the international competitive landscape;
- Execution capabilities of the participant's team: background of the founders, description of the composition of the participant's team;
- Interest and motivation to join the BioLabs Hôtel-Dieu site.

5. Golden Ticket Allocation and Conditions

The two winners of the Amgen Call for Projects will receive a priority spot for residency at Biolabs Paris for one (1) year, including the benefits related to the infrastructure and services offered by Biolabs. To accept the residency, the prize winner must sign a service agreement with Biolabs under the terms and conditions of Biolabs Paris.

The Amgen Golden Ticket grants access to a shared laboratory and an open space office at the Hotel-Dieu in Paris for one year, starting from the move-in date. The winner's occupancy at Biolabs Paris will begin when the space is available, with priority over other companies wishing to join the space. The winner will have access to the services and infrastructure provided by Biolabs Paris, such as access to events and activities organized by Biolabs, subject to availability. Equipment reservations will be made through online booking tools.

6. Confidentiality, Personal Data Protection, and Intellectual Property

From the submission of an application, all current and future exchanges between Amgen, Biolabs, and the applicants are strictly confidential, except for mandatory disclosures required by law or regulation or to satisfy a request from a competent authority.

7. Anti-Corruption Declarations and Warranty

The applicant declares, guarantees, and agrees that from the time of application and throughout the execution of their research project: i. They – as well as any person or company working on their behalf – must not, directly or indirectly, offer, pay, promise to pay, or authorize an offer, promise, payment, or transfer of any item of value to any individual or entity to obtain or maintain any business or unjustified advantage/activity related to their application or research project, which would constitute a violation of applicable laws, regulations concerning or related to public or private corruption, and commit to respecting obligations related to conflicts of interest, as defined in Articles 433-1 and following of the Penal Code; ii. The financial elements submitted as part of their application, as well as their accounting, accounts, records, and invoices, are and will be complete and accurate; iii.

Neither they nor their officers or representatives have pleaded guilty or been convicted of an offense involving fraud, corruption, and are not subject to any disqualification, suspension, disbarment proceedings, and are not otherwise declared ineligible by a government; The applicant and any person working on their behalf commit, in the exercise of their functions, to strictly comply with legal, regulatory, and professional provisions, as well as the rules of any international institution to which they are subject, and in particular not to contravene Articles 432-11 and following, 433-1 and following of the Penal Code.